RGC

Regencell Bioscience Holdings Limited

Regal Entertainment Group operates a theatre circuit in the United States. It develops, acquires, and operates multi-screen theatres in mid-sized metropolitan markets and suburban growth areas of metropolitan markets throughout United States.

Regencell Bioscience Holdings Limited (RGC) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D). The rating has held at C for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
D
Factor Score 1.4 / 5.0
Momentum
C-
Factor Score 2.1 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio N/A
EV / EBITDA -217.1
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -7.7%
Price Return 12M -63.9%
Catalyst Signal 0.00
Market Cap $2.4B
TTM Revenue N/A
Price / Sales N/A
ROE -128.5%

Historical Factor Score Progression

Held C for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 C+ (2.5) C+ (2.5) D (1.4) C- (2.1) C+ (2.6) C (2.2)
2026-11-07 C+ (2.5) C+ (2.5) D (1.5) C- (2.1) C+ (2.7) C (2.2)
2026-10-31 C+ (2.5) C+ (2.5) C- (1.9) C- (1.9) C+ (2.7) C (2.3)
2026-10-24 C+ (2.5) C+ (2.5) D+ (1.8) C- (2.0) C+ (2.6) C (2.3)
2026-10-17 C+ (2.5) C+ (2.5) D+ (1.8) C- (2.0) C+ (2.6) C (2.3)
Page 1 of 3